Good Results From Parp Inhibitor Trial
A drug trial for Olaparib, also known as Lynparza, has shown good results for women with breast cancer who have faulty variants in BRCA1 or BRCA2 genes. In the trial 85.9% of women given Olaparib for one year after the end of treatment showed no return of the cancer for three years, compared with77.1% of…